Background Largest basal diameter (LBD) appears to have independent prognostic value in uveal melanoma (UM). Methods All patients undergoing plaque brachytherapy or enucleation for UM involving the choroid and/or ciliary body between 2012 and 2019. Results A total of 348 patients with a mean age of 60±14 years were included and followed for a mean of 40±26 months (3.3±2.2 years). On multivariate analysis, LBD >12 mm remained a significant independent predictor of metastasis for both class 1 (HR 21.90; 95% CI 2.69 to 178.02; p=0.004) and class 2 (HR 2.45; 95% CI, 1.03 to 5.83; p=0.04) tumours. Four prognostic groups were created: group 1 (class 1, LBD <12 mm), group 2 (class 1, LBD ≥12 mm), group 3 (class 2, LBD <12 mm) and group 4 (class 2, LBD ≥12 mm). Life tables were used to calculate the 3-year and 5-year metastasis-free survival: group 1 (98 and 98%), group 2 (86 and 86%), group 3 (81 and 62%) and group 4 (54 and 47%). Compared with the reference category (group 1), the Cox proportional hazard model demonstrated a significant worsening of survival for each progressive category (group 2 (HR 21.59; p=0.004), group 3 (HR 47.12, p<0.001), and group 4 (HR 114.24; p<0.001)). In our dataset, the four-category Cox model performed poorer compared with the American Joint Committee on Cancer (AJCC) and gene expression profile (AJCC+GEP) in the Akaike’s information criteria (AIC) (297 vs 291), fit better with the Bayesian information criteria (BIC) (309 vs 313) and performed similarly with the Harrel’s C (0.86 (95% CI 0.80 to 0.91) vs 0.89 (0.84 to 0.94), respectively). Conclusions Combination of GEP and LBD allows separation of patients into four easy-to-use prognostic groups and was similar to a model combining AJCC stage with GEP. No data are available.

中文翻译：

---

使用结合基因表达谱和肿瘤大小的四类模型优化葡萄膜黑色素瘤早期无转移生存的预测

背景 最大基底直径 (LBD) 似乎对葡萄膜黑色素瘤 (UM) 具有独立的预后价值。方法 2012 年至 2019 年所有接受斑块近距离放射治疗或剜除术治疗脉络膜和/或睫状体 UM 的患者。结果共纳入 348 例患者，平均年龄 60±14 岁，平均随访 40±26 个月（3.3±2.2 年）。在多变量分析中，LBD >12 mm 仍然是 1 级（HR 21.90；95% CI 2.69 至 178.02；p=0.004）和 2 级（HR 2.45；95% CI，1.03 至 5.83；p =0.04) 肿瘤。创建了四个预后组：第 1 组（第 1 级，LBD <12 mm），第 2 组（第 1 级，LBD ≥12 mm），第 3 组（第 2 级，LBD <12 mm）和第 4 组（第 2 级，LBD ≥ 12 毫米）。生命表用于计算 3 年和 5 年无转移生存期：第 1 组（98 和 98%）、第 2 组（86 和 86%）、第 3 组（81 和 62%）和第 4 组（54 和 47%）。与参考类别（第 1 组）相比，Cox 比例风险模型显示每个进展类别（第 2 组（HR 21.59；p=0.004）、第 3 组（HR 47.12，p<0.001）和第4（HR 114.24；p<0.001））。在我们的数据集中，与美国癌症联合委员会 (AJCC) 和基因表达谱 (AJCC+GEP) 在 Akaike 的信息标准 (AIC) (297 vs 291) 中相比，四类 Cox 模型的表现较差，更适合贝叶斯信息标准 (BIC) (309 vs 313) 和 Harrel's C (0.86 (95% CI 0.80 to 0.91) vs 0.89 (0.84 to 0.94)) 的表现相似。结论 GEP 和 LBD 的组合允许将患者分成四个易于使用的预后组，并且类似于将 AJCC 分期与 GEP 相结合的模型。没有可用的数据。